“We are honored to welcome the Bob’s Last Marathon podcast to Penn Memory Center. We are committed to continuing its legacy by expanding access to crucial information and support for our patients and caregivers." Jason Karlawish, MD
bobsmarathon.com/podcast/ep-…
1
34
Lena celebrates the 75th episode of the podcast and recounts the significant strides in the field on many fronts—diagnosis, treatment, and importantly, caregiving.
bobsmarathon.com/podcast/ep-…
Browse by category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#PennMemoryCenter
22
“I see Steve in my children, and theirs. I find him in the stars and feel him in the gentle winds.” —Judy Johanson
bobsmarathon.com/pod.../ep-7…
Browse by category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia
27
Two caregivers share their stories in this episode: Judith Johanson and Katie Brandt, both at Massachusetts General Hospital.
bobsmarathon.com/pod.../ep-7…
Browse by category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare
32
“The greatest surprise was when I realized that grief, love, and joy could exist together in one heart: mine.” —Katie Brandt
bobsmarathon.com/pod.../ep-7…
Browse by category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare
23
What happens when we reach the end of our journey, when we are confronted with grief and loss, while the burden of caregiving is relieved? In this episode, two caregivers share their stories.
bobsmarathon.com/pod.../ep-7…
Browse by category:
bobsmarathon.com/podcasts/#b…
19
“The greatest promise of blood-based biomarkers may be in the prevention of Alzheimer’s disease.” —Dr. Steven E. Arnold
bobsmarathon.com/.../ep-73-b…
Browse by category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia
15
Faster, less expensive, and more accessible blood-based biomarkers, a long-standing goal for the medical research community, are now on the horizon.
bobsmarathon.com/.../ep-73-b…
Browse by category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#bobsmarathon #alzheimers
13
“We are now moving into a new era of treatment and prevention of Alzheimer’s disease.” — Dr. Steven E. Arnold
lnkd.in/ge6Jj5Bg
Browse by category:
lnkd.in/g9k-SkkE
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia
27
With the availability of anti-amyloid treatments for Alzheimer’s disease,, easier, less expensive, and more accessible blood-based biomarkers to correctly diagnose and stage the disease become ever more important.
lnkd.in/ge6Jj5Bg
25
“I like to frame what we have today as a huge scientific advance but a modest clinical advance.” —Dr. Steven E. Arnold
bobsmarathon.com/.../ep-72-p…
Browse category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia
While clinical trials demonstrated the ability of Leqembi (lecanemab) to clear amyloid levels, there is still cognitive decline.
bobsmarathon.com/.../ep-72-p…
Browse episodes by category:
bobsmarathon.com/podcasts/#b…
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport
“It ultimately comes down to conversations between patients and their physician and families in terms of acceptable levels of risk.” —Dr. Steven E. Arnold
bobsmarathon.com/.../ep-72-p…
bobsmarathon.com
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia
16
Genetic status can impact both potential benefit and risk in anti-amyloid therapy. The apolipoprotein E4 gene, for example, is a risk gene for both Alzheimer’s disease and side effects associated with Leqembi (lecanemab).
bobsmarathon.com/.../ep-72-p…
102
“We are very much trying to keep to the way the clinical trials were designed in terms of who we feel is appropriate for the drug.” —Dr. David A. Wolk
bobsmarathon.com/.../ep-72-p…
Browse by category:
bobsmarathon.com/podcasts/#b…
#bobsmarathon #alzheimers #alzheimerssupport #dementiacare
15
Early experience with Leqembi (lecanemab) gives clinicians insight into the challenges of administering this newly approved therapy as well as the benefits.
lnkd.in/gcfJeEcV
Browse by category:
lnkd.in/g9k-SkkE
85
“It has taken us decades and numerous failures of different treatments and billions of dollars of clinical trials to come to the point that we are now at.” —Dr. Steven E. Arnold
bobsmarathon.com/.../ep-71-p…
Browse by category:
bobsmarathon.com/podcasts/#b…
1
20
Two leading clinicians explain a key feature of new anti-amyloid therapies—that they are designed to attack oligomers rather than single protein molecules—and why this makes a difference in clinical efficacy.
bobsmarathon.com/.../ep-71-p…
Browse by category:
bobsmarathon.com/podcasts/#b…
17
“There was clear evidence of slowing of progression of the disease over the 18-month period and that’s the kind of definitive data that led the FDA to approve the drug.” —Dr. David A. Wolk
bobsmarathon.com/.../ep-71-p…
Browse by category:
bobsmarathon.com/podcasts/#b…
#alzheimers
#icym
14
Data from the 18-month multicenter clinical trial that was pivotal to the approval of Leqembi (lecanemab) demonstrated both a reduction in amyloid burden and slowing progression of cognitive decline.
bobsmarathon.com/.../ep-71-p…
Browse by category:
bobsmarathon.com/podcasts/#b…
57




















